Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01201798 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of Difluprednate 0.05% for the Treatment of Anterior Uveitis
A Phase 3 study, sponsored by Alcon Research.
- Completed
- Registry status
- Phase 3
- Development phase
- 111
- Enrollment target
NCT01201798 is a Phase 3 study that has completed, run by Alcon Research. The registered enrollment target is 111 participants.
The verdict
NCT01201798, a Phase 3 study, has completed, sponsored by Alcon Research.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 111 participants
- Enrollment target
Study Summary
The purpose of this study was to demonstrate that difluprednate 0.05% (Durezol) dosed 4 times daily is noninferior to prednisolone 1% (Pred Forte) dosed 8 times daily for the treatment of endogenous anterior uveitis.
Interventions
- DRUG Difluprednate 0.05% ophthalmic emulsion
- DRUG Prednisolone acetate 1.0% ophthalmic suspension
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 111 participants |
| Start Date | 2010-10 |
| Est. Completion | 2011-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01201798
The ClinicalTrials.gov registry entry for NCT01201798 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 111 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alcon Research, which has 275 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Difluprednate 0.05% ophthalmic emulsion is the first listed.
NCT01201798 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01201798 about?
NCT01201798 is a clinical study titled "Safety and Efficacy of Difluprednate 0.05% for the Treatment of Anterior Uveitis". The purpose of this study was to demonstrate that difluprednate 0.05% (Durezol) dosed 4 times daily is noninferior to prednisolone 1% (Pred Forte) dosed 8 times daily for the treatment of endogenous anterior uveitis.
What is the current status of trial NCT01201798?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 111 participants. The study started on 2010-10. Estimated completion is 2011-08.
What interventions are being tested in trial NCT01201798?
The interventions under investigation include: Difluprednate 0.05% ophthalmic emulsion (DRUG), Prednisolone acetate 1.0% ophthalmic suspension (DRUG).
Who is sponsoring clinical trial NCT01201798?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.